Side-by-side · Research reference

IGF-DESvsSemax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED8/60 cited

BHuman-MechanisticAUTO-DRAFTED12/39 cited

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

01Mechanism of Action

Parameter

IGF-DES

Semax

Primary target

IGF-1 receptor (IGF1R)Shields 2007

BDNF / NGF expression + monoamine modulationKaplan 2017

Pathway

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Downstream effect

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Feedback intact?

Unknown — no human endocrine feedback data

—

Origin

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

Antibody development

—

02Dosage Protocols

Parameter

IGF-DES

Semax

Research dose range

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

—

Route

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

—

Frequency

Variable — daily to multiple times daily in research

2–3× per day during cognitive demand

Evidence basis

Animal models + in vitro only

Human-mechanistic + Russian clinicalKaplan 2017

Human data

None — no clinical trials

—

Half-life

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

Short plasma; CNS effect lasts ~3–6 hr

Standard dose

—

200–600 mcg / dose intranasalKaplan 2017

Lower / starter dose

—

100 mcg / dose

Duration

—

10–14 day cycles, repeated PRN

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon

03Metabolic / Fat Loss Evidence

Parameter

IGF-DES

Semax

Primary mechanism

Indirect via muscle hypertrophy → metabolic rate elevation

—

Direct lipolysis

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

—

Prostate model

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

—

04Side Effects & Safety

Parameter

IGF-DES

Semax

Hypoglycemia risk

Theoretical — IGF-1 axis enhances glucose uptake

—

Mitogenic risk

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

—

Injection site reaction

Expected — erythema, irritation, local swelling

—

Edema / Fluid retention

Possible via sodium retention (IGF-1 axis effect)

—

Human safety data

Absent — no human trials, all effects theoretical or extrapolated

—

Unknown long-term effects

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

—

Nasal irritation

—

Mild burning or congestion (transient)

Sleep disruption

—

Late-day dosing may interfere with sleep

Headache

—

Uncommon, transient

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Semax

·Pregnancy / breastfeeding

Relative Contraindications

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

Semax

·Active psychiatric instability
·Concurrent strong stimulants

05Administration Protocol

Parameter

IGF-DES

Semax

1. Research context only

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Reconstitution (if lyophilized)

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

3. Injection site

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

Morning + early afternoon. Avoid evening (sleep disruption).

4. Timing

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

Refrigerate after reconstitution; light-protected.

5. Needle gauge

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

Cycle on/off to avoid neurochemical adaptation.

6. Monitoring

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

—

06Stack Synergy

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014